HUTCHMED (China) Limited

Good day and thank you for standing by. Welcome to HutchMED 2022 Full Year Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please press dial 11 again. Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Mr. Mark Lee, SVP, Corporate Finance and Development of HodgeMac. Please go ahead, sir.

Thank you, Amber. Welcome, everyone. Good morning, good afternoon, good evening. Welcome to the HodgeMed 2022 full-year results and business update presentation. Just at this time I'll mention that the performance and the results of our operations that we'll be talking about today are historic in nature and past performance is not guaranteed. The usage presentation does contain forward-looking statements in relation to the safe harbor provisions and anything that is said and discussed should be heard and read in conjunction with Hachmet's results that we have published on R&S, on NRSEC filings, and in our notes in Hong Kong on Stock Exchange. Today we have a broad management team for you to present and answer questions, including Weiguo Su, our Chief Executive Officer and Chief Scientific Officer, Johnny Cheng, our Chief Financial Officer, Karen Atkin, our Chief Operating Officer, Peng Chen, our Chief Commercial Officer, Mike Shi, our Chief Medical Officer and Head of R&D, Jumping Wu, our Executive Vice President of Pharmaceutical Sciences and Manufacturing, and Charles Nixon, our General Counsel. So with that, I'll hand over to Weiguo.

Okay, thank you very much, Mark. Good morning, good afternoon, good evening, everyone. Welcome again to HutchMed 2022 Four-Year Results Conference Call. A few hours ago, we announced our 2022 Four-Year Results. Mark, can you show the next slide, please? Thank you. And during 2022, HutchMed made significant strategic changes to allow us to better deal with adverse external conditions and to focus on getting to profitability sooner. On the pipeline, We made significant progress, including the positive phase three global registration study for ASCO-2 for frequentinib. And based on the strong data, NDA submissions are planned for 2023, starting from the US, followed by EU and Japan. In parallel, our second wave of products, including SolvlaPlanet, mDesilisib, and TES-Metastat, In registration trials in China also made a significant progress. China NDA submissions are planned for 2023 and 2024. Finally, on the China commercial, despite all the challenges associated with COVID and unfavorable exchange rate, our China commercial team delivered strong numbers for our three approved products. Now I'll pass it to Mr. Chen Hong, Chief Commercial Officer of China Commercial to lead it off to give you an update on the China commercial operation. Next slide, Mark, and for Chen Hong.